An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F18%3A10387152" target="_blank" >RIV/00216208:11130/18:10387152 - isvavai.cz</a>
Alternative codes found
RIV/00064203:_____/18:10387152
Result on the web
<a href="https://doi.org/10.1007/s00345-018-2380-x" target="_blank" >https://doi.org/10.1007/s00345-018-2380-x</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s00345-018-2380-x" target="_blank" >10.1007/s00345-018-2380-x</a>
Alternative languages
Result language
angličtina
Original language name
An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer
Original language description
ObjectivesWith the advent of novel genomic and transcriptomic technologies, new urinary biomarkers have been identified and tested for bladder cancer (BCa) surveillance. To summarize the current status of urinary biomarkers for the detection of recurrence and/or progression in the follow-up of non-muscle invasive BCa patients, and to assess the value of urinary biomarkers in predicting response to intravesical Bacillus Calmette-Guerin (BCG) therapy.Methods and materialsA medline/pubmed (c) literature search was performed. The performance of commercially available and investigational biomarkers has been reviewed. End points were cancer detection (recurrence), cancer progression, and response to BCG therapy.ResultsThe performance requirements for biomarkers are variable according to the clinical scenario. The clinical role of urinary biomarkers in the follow-up of non-muscle invasive BCa patients remains undefined. The FDA-approved tests provide unsatisfactory sensitivity and specificity levels and their use is limited. Fluorescence in situ hybridization (FISH) has been shown to be useful in specific scenarios, mostly as a reflex test and in the setting of equivocal urinary cytology. FISH and immunocytology could conceivably be used to assess BCG response. Recently developed biomarkers have shown promising results; upcoming large trials will test their utility in specific clinical scenarios in a manner similar to a phased drug development strategy.ConclusionsCurrent commercially available urinary biomarker-based tests are not sufficiently validated to be widely used in clinical practice. Several novel biomarkers are currently under investigation. Prospective multicenter analyses will be needed to establish their clinical relevance and value.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30217 - Urology and nephrology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2018
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
World Journal of Urology
ISSN
0724-4983
e-ISSN
—
Volume of the periodical
36
Issue of the periodical within the volume
12
Country of publishing house
US - UNITED STATES
Number of pages
15
Pages from-to
1981-1995
UT code for WoS article
000452271200010
EID of the result in the Scopus database
2-s2.0-85048836321